Brickell’s management team is comprised of seasoned executives with substantial life science industry experience gained from organizations ranging from start-ups to global pharmaceutical companies.

Reginald Hardy
Co-Founder, Chief Executive Officer and Director

Mr. Hardy has over 25 years of experience in serving as the Chief Executive Officer and/or President for publicly-traded and privately-held pharmaceutical companies.

Prior to Brickell, Mr. Hardy was the co-founder and President of Concordia Pharmaceuticals, Inc. an oncology drug development company acquired by Kadmon Corporation in 2011. Mr. Hardy was co-founder and President of SANO Corporation, a pharmaceutical company focused on the development of novel transdermal drug delivery systems that was acquired by Elan Corporation. Prior to SANO, Mr. Hardy served as the President of the generics group at IVAX Corporation.

Mr. Hardy has also held various corporate roles with Hoechst-Roussel Pharmaceuticals, Inc. and Key Pharmaceuticals, Inc. Mr. Hardy earned his B.S. degree in Pharmacy from the University of North Carolina—Chapel Hill and M.B.A. from UNC-Greensboro.

Patricia S. Walker, M.D., Ph.D.
President and Chief Scientific Officer

Patricia Walker, M.D., Ph.D. is a Board-Certified Dermatologist and Pharmaceutical industry expert specializing in the fields of medical and aesthetic dermatology. Dr. Walker is at the forefront in the arena of medical and aesthetic dermatology.

Dr. Walker previously served as Chief Medical Officer of Kythera Biopharmaceuticals, Inc. from May 2007 until March 2013. From 2004 to 2007, Dr. Walker served as Executive Vice President and Chief Scientific Officer at Allergan Medical (formerly known as Inamed Corporation). Prior to that experience, from 1997 to 2004, Dr. Walker held positions of increasing responsibility at Allergan Inc., a biomedical company, where she ultimately served as Vice President, Clinical Research and Development for skin care pharmaceuticals.

Over the past 10 years, Dr. Walker was involved in key product approvals in dermatology and aesthetic medicine including the development and approval of Tazorac®, Azelex®, Avage®, BOTOX® Cosmetic, Hylaform®, Captique®, JUVEDERM®, Bioenterics®, LAP-BAND® and Inamed® Silicone gel-filled Breast Implants, and Kybella.

Dr. Walker received an M.D. and a Ph.D. in Physiology and Biophysics from the University of Iowa. Dr. Walker completed a residency in Dermatology and a research fellowship in the Dermatology Branch, National Cancer Institute at the National Institute of Health. Dr. Walker is an active Committee Member for the American Academy of Dermatology (AAD), is a member of the American Dermatologic Association and holds medical licenses in Iowa and California. Dr. Walker also maintains a practice located in sunny Santa Barbara County.

R. Michael Carruthers
Chief Financial Officer

Mr. Carruthers has over 20 years of experience in serving as the Chief Financial Officer for publicly-traded pharmaceutical companies.

Mr. Carruthers previously served as Interim President of Nivalis Therapeutics (Nasdaq: NVLS) beginning in January 2017 and Chief Financial Officer and Secretary since February 2015. From December 1998 to February 2015, he served as Chief Financial Officer for Array BioPharma (Nasdaq: ARRY). Prior to this, his professional experience included Chief Financial Officer of Sievers Instrument, treasurer and controller for the Waukesha division of Dover Corporation and accountant with Coopers & Lybrand. Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.

Andrew Sklawer
Co-Founder and Chief Operating Officer

Mr. Sklawer has over 14 years of experience in building and operating development-stage companies.

Prior to co-founding Brickell, he served as the Head of Operations at Concordia Pharmaceuticals, Inc., an oncology drug development company acquired by Kadmon Corporation in 2011. Prior to Concordia, Mr. Sklawer held various positions with increasing responsibility at Verid, Inc., a developer of security technology prior to and subsequent to its acquisition by EMC Corporation.

Mr. Sklawer holds a B.S. degree in Marketing from the University of Florida and received his M.B.A. from the University of Miami.

Deepak Chadha, M.S., MBA, RAC
Chief R & D Officer

With more than two decades of regulatory experience, Deepak Chadha is responsible for leading Brickell’s R&D organization.

Mr. Chadha's regulatory experience encompasses regulatory submissions and projects for drugs, biologics, medical devices and combination products for clinical and marketing applications to the FDA, the EMA, as well as the global regulatory agencies. Prior to Brickell Biotech, Mr. Chadha held the role of Vice President, Global Regulatory Affairs at Suneva Medical. During his tenure, Mr. Chadha led the regulatory approval for BELLAFILL® dermal filler for acne scar correction and supported the company’s commercial products life cycle management. Before Suneva, Mr. Chadha worked at KYTHERA, where he successfully led their lead product KYBELLA® from an early clinical phase to an NDA stage, and also supported the ex-US regulatory activities. Mr. Chadha has also served as Vice President of Global Regulatory Affairs at Allergan Medical, helping build the organization’s Global Regulatory Affairs department, and was involved with the approval for JUVEDERM®, Bioenterics®, LAP-BAND® and Silicone gel-filled Breast Implants. In addition, his career has included positions of increasing responsibility at Biomeasure Inc. (IPSEN) and Stryker Biotech.

Mr. Chadha holds a BS in Pharmaceutical Sciences from Berhampur University in Orissa, India, an MS in Pharmaceutics from Hamdard University in New Delhi, India, and an MBA in International Business from California State University, Dominguez Hills.

Lawrence Romel, M.S.
Senior Vice President, Clinical Operations

Lawrence Romel has over 20 years of drug development experience in clinical and project management for multiple therapeutic indications.

Mr. Romel previously served as Vice President of Clinical Operations at Cascadian Therapeutics (aka Oncothyreon Inc.) and also served as Chief Science Advisor and Vice President of Product Development for TranSenda International, a clinical operations software company. Prior to TranSenda, Mr. Romel served as Vice President of Clinical Operations and Project Management of Xcyte Therapies Inc., Supergen and Onyx Pharmaceuticals. His breadth of experience includes the development of biologics (GVAX), viral therapies (ONYX-015), toxin-sourced therapies (Ziconotide™), small molecule-based therapies (Orathecin™, Decitabine), liposome encapsulated drug therapies (DOXIL™, Amphotec™), drug delivery devices and hospital/medical devices. He has managed Phase III development programs in both North America and Europe.

Mr. Romel holds a Master of Science degree in Chemistry from the University of Illinois, Chicago and is certified in Project Management through U.C. Berkeley.

Herbert R. Brinkman, Ph.D.
Vice President, Chemistry, Manufacturing and Controls

Dr. Brinkman brings more than 25 years of drug development experience in CMC activities ranging from early product development to commercial launch.

Prior to joining Brickell, Herb served as Director, Research and Development at KVK Tech where he oversaw the development of ophthalmic, injectable, and topical products. Previously, he was Vice President of Product Development at TOLMAR, Inc. where he was responsible for directing the formulation development, analytical development, and process engineering teams for TOLMAR’s topical dermatology and parenteral products. Prior to joining TOLMAR, Dr. Brinkman was a CMC a consultant for various small and midsize pharmaceutical companies specializing in the development of topical products. He was also Director of Product Development at Tapestry Pharmaceuticals, Inc. and NaPro BioTherapeutics, Inc. where he led the development of novel APIs and formulations in various therapeutic areas. Herb began is pharmaceutical career at Hoffmann-LaRoche, in the Pharmaceutical Process Development group, where he was involved in the development and scale up of 4 NDA products, including Xedola® (Capecitabine) and Rocaltrol® (Calcitriol).

Dr. Brinkman holds a BA in Chemistry from Rutgers University and a Ph.D. in Organic Chemistry from Seton Hall University.

Michael P. Doyle, Ph.D.
Vice President, Global Regulatory Affairs

Dr. Doyle has worked in the pharmaceutical industry for over 23 years with the last 15 years in Regulatory Affairs.

Prior to Brickell, Dr. Doyle served as Senior Director, Regulatory Affairs at Clovis Oncology where he was responsible for Regulatory Affairs strategy and operations in support of oncology clinical trials in the US, Canada, and the EU. Prior to joining Clovis, Dr. Doyle was Global Head of Regulatory Affairs at Novella Clinical, a clinical research organization specializing in oncology, where he was responsible for all aspects of regulatory support. Before Novella, Dr. Doyle held senior management positions in Regulatory Affairs at OSI Pharmaceuticals and Array BioPharma.

Before moving into Regulatory Affairs, Dr. Doyle held scientific positions with Somatogen and Baxter Healthcare, most recently serving as Senior Research Scientist supporting Baxter’s Hemoglobin Therapeutics program. Dr. Doyle holds a Ph.D. in physiology from the University of New Mexico School of Medicine and completed four years of post doctoral training at the University of Virginia Health Sciences Center.